Business
Mol Cancer Ther Publishes Bexmarilimab Research
Mol Cancer Ther Publishes Bexmarilimab Research.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 6854K\n Faron Pharmaceuticals Oy\n 09 May 2022\n \n \n \n \n Faron Pharmaceuticals Ltd.\n \n \n (\"Faron\" or \"Company\")\n \n \n \n \n \n \n Molecular Cancer Therapeutics\n \n \n Publishes Research on the Nonclinical Characterization of Bexmarilimab\n \n \n \n \n \n \n \n \n \n Press release, May 9, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST)\n \n \n \n \n \n \n TURKU, FINLAND / BOSTON, MA\n \n \n \n \n - Faron Pharmaceuticals Ltd (\n AIM: FARN, First North: FARON\n ), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the American Association for Cancer Research (AACR) journal Molecular Cancer Therapeutics\n published research examining the discovery and preclinical development of bexmarilimab, Faron's wholly-owned investigational precision cancer immunotherapy. The paper, titled \"Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers\" is available online at: \n \n \n https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-21-0840/696262/Nonclinical-characterization-of-bexmarilimab-a\n \n \n . \n \n \n \n \n \n The manuscript details early research from the bexmarilimab program and explores the hypothesis that Clever-1, a protein that is highly expressed in a subset of immunosuppressive human tumor-associated macrophages and is associated with poor patient outcomes following treatment with currently approved checkpoint inhibitors, is a novel target for the development of next generation immunotherapies. Tumor-associated macrophages are one of the main contributors to an immunosuppressive tumor microenvironment and the inhibition of Clever-1 has been demonstrated to convert immunosuppressive M2 macrophages into immunostimulatory M1 macrophages. In the paper, the authors discuss the potential of Clever-1 as a therapeutic target and that downregulating Clever-1 could lead to T-cell activation and restoration of an immune response in cancer patients. \n \n \n \n \n \n Reporting the humanization and nonclinical characterization steps used to determine the physicochemical properties, biological potency, and safety profile of bexmarilimab, ...